Obesity is a major driver of metabolic diseases, including type 2 diabetes, metabolic syndrome, dyslipidemia, hypercholesterolemia, and obesity-associated cardiovascular disease. As the prevalence of obesity continues to rise worldwide, there is an increasing need for translational preclinical models that faithfully recapitulate human metabolic dysfunction and enable robust evaluation of next-generation therapeutics. Diet-induced obesity (DIO) mouse models have become one of the most widely used and well-validated preclinical models for studying obesity-associated metabolic disorders and evaluating therapeutic efficacy.
In this webinar, we will review the current landscape of metabolic disease therapeutics and introduce Biocytogen's integrated DIO platform together with its portfolio of humanized animal models designed to accelerate metabolic disease research and therapeutic development. The platform supports evaluation of diverse therapeutic modalities, including small molecules, biologics, oligonucleotide therapeutics, cell therapies, and gene-editing approaches. We will discuss integrated phenotyping capabilities that enable comprehensive assessment of obesity, glucose homeostasis, lipid metabolism, energy expenditure, body composition, and cardiometabolic health, supporting both mechanism-of-action studies and efficacy evaluation.
Join us to learn how Biocytogen's integrated preclinical platform supports target validation, mechanism-of-action studies, and efficacy evaluation to accelerate the development of therapies for obesity and related metabolic diseases.
What you will discover:
Speaker:
Dong Han, Ph.D., Director of Pharmacology Platform
Panelist:
Wei-Chieh Mu, Ph.D., Business Development Manager
Woonyen Wong, Ph.D., Senior Scientist I
